Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation

被引：34

作者：

Takahashi, Wakana ^{[1
]}

Yoneda, Taro ^{[1
]}

Koba, Hayato ^{[1
]}

Ueda, Tsukasa ^{[1
]}

Tsuji, Noriaki ^{[1
]}

Ogawa, Haruhiko ^{[2
]}

Asakura, Hidesaku ^{[3
]}

机构：

[1] Komatsu Municipal Hosp, Dept Internal Med, Ho 60,Mukaimotoori Machi, Komatsu, Ishikawa 9238560, Japan

[2] Kanazawa Univ, Dept Environm & Prevent Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan

[3] Kanazawa Univ Hosp, Dept Hematol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 102卷

关键词：

COVID-19; Disseminated intravascular coagulation; Nafamostat; Serine proteinase inhibitor;

D O I：

10.1016/j.ijid.2020.10.093

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Nafamostat, a serine proteinase inhibitor with various actions including antithrombin, antiplasmin, and antitrypsin effects, has been used in clinical practice to treat disseminated intravascular coagulation (DIC) and pancreatitis. This case report describes the clinical course of a patient with COVID-19 pneumonia whose severe hypoxemia, probably caused by DIC and pulmonary embolism, showed remarkable improvement with combination heparin and nafamostat therapy. In addition, beneficial mechanisms of nafamostat against COVID-19 and the necessity of attention to hyperkalemia as an adverse effect are discussed. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

引用

页码：529 / 531

页数：3

共 15 条

[1] PHARMACOLOGICAL STUDIES OF FUT-175, NAFAMSTAT MESILATE .1. INHIBITION OF PROTEASE ACTIVITY IN INVITRO AND INVIVO EXPERIMENTS [J].